Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Review Article

Antiviral Effects of Asian Natural Products Targeting SARS, MERS, and COVID-19

Author(s): Jafrin Jobayer Sonju, Md. Rafi Anwar*, Md. Abul Kalam Azad, Umme Habiba Sultana, Kumar Kulldeep Niloy and Sajan Das

Volume 2, Issue 7, 2021

Published on: 27 January, 2021

Article ID: e250621190796 Pages: 18

DOI: 10.2174/2666796702666210127111918

Abstract

diseases initiated by Coronavirus (CoV) have become the major public health problems worldwide in the last two decades. The recent emergence of the deadly COVID-19 due to SARS-CoV-2 has created unprecedented pandemic situations around the globe making the need for antiviral molecules to treat it. Encountering the health conditions of the patients with synthetic molecules has shown some unpredictable results, including side effects. To face this complex situation, natural products can be good sources of enormous treatment options with fewer side effects. Wide diversity, easy availability, and a good number of scientific researches on Asian origin natural products can be a great tool to meet this critical situation. This paper reviews the currently available Asian natural products with potential antiviral effects on CoV. It includes the potential natural products of whole plant extract, partial plant extract, isolated pure compounds, and isolated pure set of compounds. Besides, the available information of in vitro and in silico from very recent papers are also summarized for the ease of future research. As a rapid search for a potential anti-CoV therapy is undergoing, Asian natural products will provide promising results but still, there are many challenges in front of us, including the robust in vitro assay to confirm the antiviral property, toxicity analysis, and fulfillment of regulatory needs. The use of appropriate natural products with the potential for a safe and more effective anti-CoV property requires multidisciplinary research with preclinical and clinical researchers, which will improve their clinical applications.

Keywords: Coronavirus, Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), COVID-19, SARS-CoV-2, Asian natural products, in vitro studies, in silico studies.

[1]
Jin Y, Yang H, Ji W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020; 12(4): 372.
[http://dx.doi.org/10.3390/v12040372] [PMID: 32230900]
[2]
Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020; 24: 91-8.
[http://dx.doi.org/10.1016/j.jare.2020.03.005] [PMID: 32257431]
[3]
Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses 2020; 12(2): 12.
[http://dx.doi.org/10.3390/v12020135] [PMID: 31991541]
[4]
Burki TK. Coronavirus in China. Lancet Respir Med 2020; 8(3): 238.
[http://dx.doi.org/10.1016/S2213-2600(20)30056-4] [PMID: 32027848]
[5]
The World Health Organization. The World Health Organization (WHO) has officially named the disease caused by the novel coronavirus as COVID-19. Available from: https://www.history.com/this-day-in-history/world-health-organization-officially-names-coronavirus-covid19
[6]
Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the coronavirus study group. bioRxiv 2020.
[7]
Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed 2020; 91(1): 157-60.
[PMID: 32191675]
[8]
Coronavirus disease (COVID-19) Pandemic 2020. Coronavirus disease (COVID-19) outbreak situation 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
[9]
Q&A on coronaviruses Is there a treatment for a novel coronavirus? Available from: https://www.researchgate.net/post/Is_there_a_treatment_for_a_novel_coronavirus
[10]
WHO. WHO coronavirus disease (COVID-19) dashboard Available from: https://covid19.who.int/
[11]
Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet 2003; 362(9393): 1353-8.
[http://dx.doi.org/10.1016/S0140-6736(03)14630-2] [PMID: 14585636]
[12]
Wang N, Shi X, Jiang L, et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 2013; 23(8): 986-93.
[http://dx.doi.org/10.1038/cr.2013.92] [PMID: 23835475]
[13]
Runfeng L, Yunlong H, Jicheng H, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res 2020; 156: 104761.
[http://dx.doi.org/10.1016/j.phrs.2020.104761] [PMID: 32205232]
[14]
Elfiky AA. Natural products may interfere with SARS-CoV-2 attachment to the host cell. J Biomol Struct Dyn 2020; 39: 1-10.
[http://dx.doi.org/10.1080/07391102.2020.1761881] [PMID: 32340551]
[15]
Zhang DH, Wu KL, Zhang X, Deng SQ, Peng B. In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus. J Integr Med 2020; 18(2): 152-8.
[http://dx.doi.org/10.1016/j.joim.2020.02.005] [PMID: 32113846]
[16]
Maiti S, Banerjee A, Nazmeen A, Kanwar M, Das S. Active-site Molecular docking of Nigellidine to nucleocapsid/Nsp2/Nsp3/MPro of COVID-19 and to human IL1R and TNFR1/2 may stop viral-growth/cytokine-flood, and the drug source Nigella sativa (black cumin) seeds show potent antioxidant role in experimental rats. Research Square. Available from: https://www.researchsquare.com/article/rs-26464/v1
[17]
Salim B, Noureddine M. Identification of compounds from nigella sativa as new potential inhibitors of 2019 novel coronavirus (covid-19). Molecular docking Study. ChemRxiv 2020. Available from: https://chemrxiv.org/articles/preprint/Identification_of_Compounds_from_Nigella_Sativa_as_New_Potential_Inhibitors_of_2019_Novel_Coronasvirus_Covid-19_Molecular_Docking_Study_/12055716/1
[18]
Lin CW, Tsai FJ, Tsai CH, et al. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antiviral Res 2005; 68(1): 36-42.
[http://dx.doi.org/10.1016/j.antiviral.2005.07.002] [PMID: 16115693]
[19]
Ulasli M, Gurses SA, Bayraktar R, et al. The effects of Nigella sativa (Ns), Anthemis hyalina (Ah) and Citrus sinensis (Cs) extracts on the replication of coronavirus and the expression of TRP genes family. Mol Biol Rep 2014; 41(3): 1703-11.
[http://dx.doi.org/10.1007/s11033-014-3019-7] [PMID: 24413991]
[20]
Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020; 19(3): 149-50.
[http://dx.doi.org/10.1038/d41573-020-00016-0] [PMID: 32127666]
[21]
Liu J, Manheimer E, Shi Y, Gluud C. Chinese herbal medicine for severe acute respiratory syndrome: A systematic review and meta-analysis. J Altern Complement Med 2004; 10(6): 1041-51.
[http://dx.doi.org/10.1089/acm.2004.10.1041] [PMID: 15674000]
[22]
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270-3.
[http://dx.doi.org/10.1038/s41586-020-2012-7] [PMID: 32015507]
[23]
Wu A, Peng Y, Huang B, et al. Genome composition and divergence of the novel Coronavirus (2019-nCoV) originating in China. Cell Host Microbe 2020; 27(3): 325-8.
[http://dx.doi.org/10.1016/j.chom.2020.02.001] [PMID: 32035028]
[24]
Leung PC. The efficacy of Chinese medicine for SARS: A review of Chinese publications after the crisis. Am J Chin Med 2007; 35(4): 575-81.
[http://dx.doi.org/10.1142/S0192415X07005077] [PMID: 17708624]
[25]
de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ. Host factors in coronavirus replication roles of host gene and non-coding RNA expression in virus infection. Cham: Springer international publishing 2018; pp. 1-42.
[26]
Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res 2011; 81: 85-164.
[http://dx.doi.org/10.1016/B978-0-12-385885-6.00009-2] [PMID: 22094080]
[27]
Zhu N, Zhang D, Wang W, et al. China novel coronavirus investigating and research team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727-33.
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]
[28]
Wu F, Zhao S, Yu B, et al. Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China. bioRxiv 2020.
[29]
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020; 395(10224): 565-74.
[http://dx.doi.org/10.1016/S0140-6736(20)30251-8] [PMID: 32007145]
[30]
Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol 2020; 92(4): 418-23.
[http://dx.doi.org/10.1002/jmv.25681] [PMID: 31967327]
[31]
Hui DSI, I Azhar E, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 2020; 91: 264-6.
[http://dx.doi.org/10.1016/j.ijid.2020.01.009] [PMID: 31953166]
[32]
Li B, Si HR, Zhu Y, et al. Discovery of bat coronaviruses through surveillance and probe capture-based next-generation sequencing. MSphere 2020; 5(1): e00807-19.
[http://dx.doi.org/10.1128/mSphere.00807-19] [PMID: 31996413]
[33]
Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 2020; 63(3): 457-60.
[http://dx.doi.org/10.1007/s11427-020-1637-5] [PMID: 32009228]
[34]
Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS Coronavirus. J Virol 2020; 94(7): 94.
[http://dx.doi.org/10.1128/JVI.00127-20] [PMID: 31996437]
[35]
van Boheemen S, de Graaf M, Lauber C, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 2012; 3(6): 3.
[http://dx.doi.org/10.1128/mBio.00473-12] [PMID: 23170002]
[36]
Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495(7440): 251-4.
[http://dx.doi.org/10.1038/nature12005] [PMID: 23486063]
[37]
Perlman S, Netland J. Coronaviruses post-SARS: Update on replication and pathogenesis. Nat Rev Microbiol 2009; 7(6): 439-50.
[http://dx.doi.org/10.1038/nrmicro2147] [PMID: 19430490]
[38]
Glowacka I, Bertram S, Müller MA, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol 2011; 85(9): 4122-34.
[http://dx.doi.org/10.1128/JVI.02232-10] [PMID: 21325420]
[39]
Bertram S, Glowacka I, Müller MA, et al. Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. J Virol 2011; 85(24): 13363-72.
[http://dx.doi.org/10.1128/JVI.05300-11] [PMID: 21994442]
[40]
Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020; 579(7798): 265-9.
[http://dx.doi.org/10.1038/s41586-020-2008-3] [PMID: 32015508]
[41]
Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med 2020; 26(4): 450-2.
[http://dx.doi.org/10.1038/s41591-020-0820-9] [PMID: 32284615]
[42]
Vijaykrishna D, Smith GJD, Zhang JX, Peiris JSM, Chen H, Guan Y. Evolutionary insights into the ecology of coronaviruses. J Virol 2007; 81(8): 4012-20.
[http://dx.doi.org/10.1128/JVI.02605-06] [PMID: 17267506]
[43]
Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and sources of endemic human Coronaviruses. Adv Virus Res 2018; 100: 163-88.
[http://dx.doi.org/10.1016/bs.aivir.2018.01.001] [PMID: 29551135]
[44]
Ge XY, Li JL, Yang XL, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 2013; 503(7477): 535-8.
[http://dx.doi.org/10.1038/nature12711] [PMID: 24172901]
[45]
Lau SK, Woo PC, Li KS, et al. Severe acute respiratory syndrome coronavirus-like virus in chinese horseshoe bats. Proc Natl Acad Sci USA 2005; 102(39): 14040-5.
[http://dx.doi.org/10.1073/pnas.0506735102] [PMID: 16169905]
[46]
Lam TT-Y, Shum MH-H, Zhu H-C, et al. Identification of 2019-nCoV related coronaviruses in Malayan pangolins in southern China. bioRxiv 2020.
[47]
Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020; 158(6): 1831-1833.e3.
[http://dx.doi.org/10.1053/j.gastro.2020.02.055] [PMID: 32142773]
[48]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[49]
Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020; 97(5): 829-38.
[http://dx.doi.org/10.1016/j.kint.2020.03.005] [PMID: 32247631]
[50]
Guan GW, Gao L, Wang JW, et al. [Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia]. Zhonghua Gan Zang Bing Za Zhi 2020; 28(2): 100-6.
[PMID: 32077659]
[51]
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan. China. JAMA 2020; 323(11): 1061-9.
[http://dx.doi.org/10.1001/jama.2020.1585] [PMID: 32031570]
[52]
Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 2020; 14(2): 185-92.
[http://dx.doi.org/10.1007/s11684-020-0754-0] [PMID: 32170560]
[53]
Fan C, Li K, Ding Y, Lu WL, Wang J. ACE2 expression in kidney and testis may cause kidney and testis damage after 2019-nCoV infection. medRxiv 2020.
[54]
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8(4): 420-2.
[http://dx.doi.org/10.1016/S2213-2600(20)30076-X] [PMID: 32085846]
[55]
Ding Y, Wang H, Shen H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): A report from China. J Pathol 2003; 200(3): 282-9.
[http://dx.doi.org/10.1002/path.1440] [PMID: 12845623]
[56]
Ng DL, Al Hosani F, Keating MK, et al. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of middle east respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. Am J Pathol 2016; 186(3): 652-8.
[http://dx.doi.org/10.1016/j.ajpath.2015.10.024] [PMID: 26857507]
[57]
Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: From mechanisms to potential therapeutic tools. Virol Sin 2020; 35(3): 266-71.
[http://dx.doi.org/10.1007/s12250-020-00207-4] [PMID: 32125642]
[58]
Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med 2005; 202(3): 415-24.
[http://dx.doi.org/10.1084/jem.20050828] [PMID: 16043521]
[59]
Yang M. Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection. 2019. Available from: https://ssrn.com/abstract=3527420
[60]
Imai Y, Kuba K, Penninger JM. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp Physiol 2008; 93(5): 543-8.
[http://dx.doi.org/10.1113/expphysiol.2007.040048] [PMID: 18448662]
[61]
Takada A, Kawaoka Y. Antibody-dependent enhancement of viral infection: Molecular mechanisms and in vivo implications. Rev Med Virol 2003; 13(6): 387-98.
[http://dx.doi.org/10.1002/rmv.405] [PMID: 14625886]
[62]
Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. N Engl J Med 2017; 377(6): 562-72.
[http://dx.doi.org/10.1056/NEJMra1608077] [PMID: 28792873]
[63]
Meyer NJ, Christie JD. Genetic heterogeneity and risk of acute respiratory distress syndrome. Semin Respir Crit Care Med 2013; 34(4): 459-74.
[http://dx.doi.org/10.1055/s-0033-1351121] [PMID: 23934715]
[64]
Gretebeck LM, Subbarao K. Animal models for SARS and MERS coronaviruses. Curr Opin Virol 2015; 13: 123-9.
[http://dx.doi.org/10.1016/j.coviro.2015.06.009] [PMID: 26184451]
[65]
Nagata N, Iwata N, Hasegawa H, et al. Participation of both host and virus factors in induction of severe acute respiratory syndrome (SARS) in F344 rats infected with SARS coronavirus. J Virol 2007; 81(4): 1848-57.
[http://dx.doi.org/10.1128/JVI.01967-06] [PMID: 17151094]
[66]
Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11(1): 222.
[http://dx.doi.org/10.1038/s41467-019-13940-6] [PMID: 31924756]
[67]
Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 2020; 14(1): 64-8.
[http://dx.doi.org/10.5582/bst.2020.01030] [PMID: 32037389]
[68]
Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020; 395(10223): e30-1.
[http://dx.doi.org/10.1016/S0140-6736(20)30304-4] [PMID: 32032529]
[69]
Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the united states. N Engl J Med 2020; 382(10): 929-36.
[http://dx.doi.org/10.1056/NEJMoa2001191] [PMID: 32004427]
[70]
Ng CS, Kasumba DM, Fujita T, Luo H. Spatio-temporal characterization of the antiviral activity of the XRN1-DCP1/2 aggregation against cytoplasmic RNA viruses to prevent cell death. Cell Death Differ 2020; 27(8): 2363-82.
[http://dx.doi.org/10.1038/s41418-020-0509-0] [PMID: 32034313]
[71]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro . Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[72]
Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro . Cell Discov 2020; 6: 16.
[http://dx.doi.org/10.1038/s41421-020-0156-0]
[73]
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro . Antiviral Res 2020; 178: 104787.
[http://dx.doi.org/10.1016/j.antiviral.2020.104787] [PMID: 32251768]
[74]
Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017; 9(396): 9.
[http://dx.doi.org/10.1126/scitranslmed.aal3653] [PMID: 28659436]
[75]
Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol 2020; 92(5): 479-90.
[http://dx.doi.org/10.1002/jmv.25707] [PMID: 32052466]
[76]
De Clercq E. New nucleoside analogues for the treatment of hemorrhagic fever virus infections. Chem Asian J 2019; 14(22): 3962-8.
[http://dx.doi.org/10.1002/asia.201900841] [PMID: 31389664]
[77]
Habibzadeh P, Stoneman EK. The novel coronavirus: A bird’s eye view. Int J Occup Environ Med 2020; 11(2): 65-71.
[http://dx.doi.org/10.15171/ijoem.2020.1921] [PMID: 32020915]
[78]
Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020; 7(1): 4.
[http://dx.doi.org/10.1186/s40779-020-0233-6] [PMID: 32029004]
[79]
Jordan PC, Stevens SK, Deval J. Nucleosides for the treatment of respiratory RNA virus infections. Antivir Chem Chemother 2018; 26: 2040206618764483.
[http://dx.doi.org/10.1177/2040206618764483] [PMID: 29562753]
[80]
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020; 395(10223): 507-13.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]
[81]
Sewell HF, Agius RM, Kendrick D, Stewart M. Vaccines, convalescent plasma, and monoclonal antibodies for covid-19. BMJ 2020; 370: m2722.
[http://dx.doi.org/10.1136/bmj.m2722] [PMID: 32646867]
[82]
Ryu YB, Jeong HJ, Kim JH, et al. Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition. Bioorg Med Chem 2010; 18(22): 7940-7.
[http://dx.doi.org/10.1016/j.bmc.2010.09.035] [PMID: 20934345]
[83]
Park JY, Ko JA, Kim DW, et al. Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV. J Enzyme Inhib Med Chem 2016; 31(1): 23-30.
[http://dx.doi.org/10.3109/14756366.2014.1003215] [PMID: 25683083]
[84]
Chi JH, Kim YH, Sohn DH, Seo GS, Lee SH. Ameliorative effect of Alnus japonica ethanol extract on colitis through the inhibition of inflammatory responses and attenuation of intestinal barrier disruption in vivo and in vitro . Biomed Pharmacother 2018; 108: 1767-74.
[http://dx.doi.org/10.1016/j.biopha.2018.10.050] [PMID: 30372880]
[85]
Hess W, Mackeen MM, Kramer HB. Chapter 6 - natural product inhibitors of ubiquitin conjugation and deconjugation.Studies in natural products chemistry. Elsevier 2016; 69: pp. 207-42.
[86]
Kim JY, Kim YI, Park SJ, Kim IK, Choi YK, Kim SH. Safe, high-throughput screening of natural compounds of MERS-CoV entry inhibitors using a pseudovirus expressing MERS-CoV spike protein. Int J Antimicrob Agents 2018; 52(5): 730-2.
[http://dx.doi.org/10.1016/j.ijantimicag.2018.05.003] [PMID: 29772395]
[87]
Yoon JH, Lee J, Lee JY, et al. Study on the 2-Phenylchroman-4-One derivatives and their anti-MERS-CoV activities. Bull Korean Chem Soc 2019; 40(9): 906-9.
[http://dx.doi.org/10.1002/bkcs.11832] [PMID: 32313350]
[88]
Jadav SS, Ganta NM, Kumar A, Dan N, Mohanty NP. The updates on middle east respiratory syndrome coronavirus (mers-cov) epidemiology, pathogenesis, viral genome and currently available drugs. J Pharm Sci 2016; 3: 1-9.
[89]
Islam MT, Sarkar C, El-Kersh DM, et al. Natural products and their derivatives against coronavirus: A review of the non-clinical and pre-clinical data. Phytother Res 2020; 34(10): 2471-92.
[http://dx.doi.org/10.1002/ptr.6700] [PMID: 32248575]
[90]
Utomo RYIM, Meiyanto E. Revealing the potency of citrus and galangal constituents to halt SARS-CoV-2 infection. Preprints 2020; 20: 20030214.
[http://dx.doi.org/10.20944/preprints202003.0214.v1]
[91]
Omar S, Bouziane I, Bouslama Z, Djemel A. In-silico identification of potent inhibitors of COVID-19 main protease (Mpro) and angiotensin converting enzyme 2 (ace2) from natural products: Quercetin, hispidulin, and cirsimaritin exhibited better potential inhibition than hydroxy-chloroquine against covid-19 main protease active site and ACE2. ChemRxiv 2020. Available from: https://chemrxiv.org/articles/preprint/In-Silico_Identification_of_Potent_Inhibitors_of_COVID-19_Main_Protease_Mpro_and_Angiotensin_Converting_Enzyme_2_ACE2_from_Natural_Products_Quercetin_Hispidulin_and_Cirsimaritin_Exhibited_Better_Potential_Inhibition_than_Hydroxy-Chloroquine/12181404/1
[92]
Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): A review and perspective. Int J Biol Sci 2020; 16(10): 1708-17.
[http://dx.doi.org/10.7150/ijbs.45538] [PMID: 32226288]
[93]
Zhu J, Deng Y-Q, Wang X, et al. An artificial intelligence system reveals liquiritin inhibits SARS-CoV-2 by mimicking type I interferon. bioRxiv 2020.
[94]
Heba H. In silico approach of some selected honey constituents as SARS-CoV-2 main protease (COVID-19) inhibitors. EJMO 2020; 4(3): 196-200.
[95]
al-Shamaony L, al-Khazraji SM, Twaij HA. Hypoglycaemic effect of Artemisia herba alba. II. Effect of a valuable extract on some blood parameters in diabetic animals. J Ethnopharmacol 1994; 43(3): 167-71.
[http://dx.doi.org/10.1016/0378-8741(94)90038-8] [PMID: 7990489]
[96]
Sinha SK, Shakya A, Prasad SK, et al. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets. J Biomol Struct Dyn 2020; 39: 1-12.
[http://dx.doi.org/10.1080/07391102.2020.1762741] [PMID: 32345124]
[97]
Emam AM, Diaz-Lanza AM, Matellano-Fernandez L, Faure R, Moussa AM, Balansard G. Biological activities of buddlejasaponin isolated from Buddleja madagascariensis and Scrophularia scorodonia. Pharmazie 1997; 52(1): 76-7.
[PMID: 9035239]
[98]
Lang SJ, Schmiech M, Hafner S, et al. Antitumor activity of an Artemisia annua herbal preparation and identification of active ingredients. Phytomedicine 2019; 62: 152962.
[http://dx.doi.org/10.1016/j.phymed.2019.152962] [PMID: 31132755]
[99]
Shi T, Yue Y, Shi M, Chen M, Yang X, Wang L. Exploration of floral volatile organic compounds in six typical Lycoris Taxa by GC-MS. Plants (Basel) 2019; 8(10): 422.
[http://dx.doi.org/10.3390/plants8100422] [PMID: 31627411]
[100]
Wang YR, Yang WD. Lithagogue effects of Pyrrosia lingua from Guizhou province on experimental renal calculus in rats. Zhongguo Zhongyao Zazhi 2018; 43(16): 3291-300.
[http://dx.doi.org/10.19540/j.cnki.cjcmm.20180514.005] [PMID: 30200732]
[101]
Han Z, Su H, Chen N, Luan L, Wu Y. Simultaneous determination of four alkaloids in Lindera aggregate by high performance liquid chromatography. Zhongguo Zhongyao Zazhi 2009; 34(5): 583-6.
[PMID: 19526789]
[102]
Chen Y, Fan CL, Wang Y, Zhang XQ, Huang XJ, Ye WC. Chemical constituents from roots of Isatis indigotica. Zhongguo Zhongyao Zazhi 2018; 43(10): 2091-6.
[PMID: 29933676]
[103]
Khan MA, Chen HC, Tania M, Zhang DZ. Anticancer activities of Nigella sativa (black cumin). Afr J Tradit Complement Altern Med 2011; 8(5)(Suppl.): 226-32.
[http://dx.doi.org/10.4314/ajtcam.v8i5S.10] [PMID: 22754079]
[104]
Chang JS, Wang KC, Yeh CF, Shieh DE, Chiang LC. Fresh ginger (Zingiber officinale) has anti-viral activity against human respiratory syncytial virus in human respiratory tract cell lines. J Ethnopharmacol 2013; 145(1): 146-51.
[http://dx.doi.org/10.1016/j.jep.2012.10.043] [PMID: 23123794]
[105]
Shingnaisui K, Dey T, Manna P, Kalita J. Therapeutic potentials of Houttuynia cordata Thunb. against inflammation and oxidative stress: A review. J Ethnopharmacol 2018; 220: 35-43.
[http://dx.doi.org/10.1016/j.jep.2018.03.038] [PMID: 29605674]
[106]
Sampangi-Ramaiah MH, Vishwakarma R, Shaanker RU. Molecular docking analysis of selected natural products from plants for inhibition of SARS-CoV-2 main protease. Curr Sci 2020; 118: 1087-92.
[107]
Asaduzzaman Khan M, Tania M, Fu S, Fu J. Thymoquinone, as an anticancer molecule: From basic research to clinical investigation. Oncotarget 2017; 8(31): 51907-19.
[http://dx.doi.org/10.18632/oncotarget.17206] [PMID: 28881699]
[108]
Ahmad A, Rehman MU, Alkharfy KM. An alternative approach to minimize the risk of coronavirus (Covid-19) and similar infections. Eur Rev Med Pharmacol Sci 2020; 24(7): 4030-4.
[http://dx.doi.org/10.26355/eurrev_20200420873] [PMID: 32329879]
[109]
Hensel A, Bauer R, Heinrich M, et al. Challenges at the time of COVID-19: Opportunities and innovations in antivirals from nature. Planta Med 2020; 86(10): 659-64.
[http://dx.doi.org/10.1055/a-1177-4396] [PMID: 32434254]
[110]
Yang R, Liu H, Bai C, et al. Chemical composition and pharmacological mechanism of qingfei paidu decoction and ma xing shi gan decoction against coronavirus disease 2019 (COVID-19): In silico and experimental study. Pharmacol Res 2020; 157: 104820.
[http://dx.doi.org/10.1016/j.phrs.2020.104820] [PMID: 32360484]
[111]
Williamson G, Kerimi A. Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) viral spike protein-angiotensin converting enzyme-2 (ACE2) interaction. Biochem Pharmacol 2020; 178: 114123.
[http://dx.doi.org/10.1016/j.bcp.2020.114123] [PMID: 32593613]

© 2022 Bentham Science Publishers | Privacy Policy